Lista de obras - Mathias Witzens-Harig - Dominio Público Uruguay

A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse la

artículo científico publicado en 2013

Chest Pain, Shortness of Breath, and Palpitations Unmask an Unexpected Diagnosis ⬇️

artículo científico publicado el 14 de febrero de 2012

Excellent long-term survival of 170 patients with Waldenström’s macroglobulinemia treated in private oncology practices and a university hospital ⬇️

artículo científico publicado el 16 de agosto de 2012

Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost‐effective and safer treatment of advanced follicular lymphoma ⬇️

artículo científico publicado el 27 de julio de 2012

HTLV-1-associated adult T cell leukemia is highly susceptible to Navitoclax due to enhanced Bax expression

artículo científico publicado en 2015

Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

artículo científico publicado en 2017

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting.

artículo científico publicado en 2017

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

artículo científico

Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells

artículo científico publicado en 2017

Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells

artículo científico publicado en 2007

Mild bleeding diathesis in a 62-year-old woman with hereditary thrombocytopenia

artículo científico publicado en 2013

Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma ⬇️

artículo científico publicado el 29 de noviembre de 2010

Performance assessment and benchmarking of autologous peripheral blood stem cell collection with two different apheresis devices

artículo científico publicado en 2016

Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy ⬇️

artículo científico publicado el 21 de septiembre de 2010

Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors ⬇️

artículo científico publicado el 18 de agosto de 2011

Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma

artículo científico publicado en 2014

Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials ⬇️

artículo científico publicado el 21 de octubre de 2011

Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy ⬇️

artículo científico publicado el 22 de mayo de 2012

Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial.

artículo científico publicado en 2015

Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma

artículo científico publicado en 2015

Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma

artículo científico publicado en 2012

The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma

artículo científico publicado en 2013

The impact of high-dose chemotherapy, autologous stem cell transplant and conventional chemotherapy on quality of life of long-term survivors with follicular lymphoma

artículo científico publicado en 2011

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas

artículo científico publicado en 2014

Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial

artículo científico publicado en 2011

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies

artículo científico publicado en 2012

Lista de obras de Mathias Witzens-Harig

A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse la

Chest Pain, Shortness of Breath, and Palpitations Unmask an Unexpected Diagnosis ⬇️

Excellent long-term survival of 170 patients with Waldenström’s macroglobulinemia treated in private oncology practices and a university hospital ⬇️

Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost‐effective and safer treatment of advanced follicular lymphoma ⬇️

HTLV-1-associated adult T cell leukemia is highly susceptible to Navitoclax due to enhanced Bax expression

Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting.

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells

Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells

Mild bleeding diathesis in a 62-year-old woman with hereditary thrombocytopenia

Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma ⬇️

Performance assessment and benchmarking of autologous peripheral blood stem cell collection with two different apheresis devices

Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy ⬇️

Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors ⬇️

Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma

Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials ⬇️

Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy ⬇️

Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial.

Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma

Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma

The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma

The impact of high-dose chemotherapy, autologous stem cell transplant and conventional chemotherapy on quality of life of long-term survivors with follicular lymphoma

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas

Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies